Xintela AB (publ) (STO: XINT)

Market Cap	329.88M
Revenue (ttm)	381.00K
Net Income (ttm)	-40.83M
Shares Out	568.76M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,275,958
Open	0.590
Previous Close	0.540
Day's Range	0.555 - 0.630
52-Week Range	0.210 - 0.650
Beta	1.58
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2023, DevPort AB's revenue was 550.43 million, an increase of 4.32% compared to the previous year's 527.63 million. Earnings were 35.41 million, a decrease of -1.30%.